Industry Briefs
Label Changes for Geodon, Daytrana, and Tegretol
Recently, the Food and Drug Administration (FDA) announced labeling changes for the following products:
Daytrana (methylphenidate transdermal system): warning for risk of persistent loss of skin pigmentation at and around the application site
Geodon (ziprasidone) Oral Suspension, Injection, and Capsule: warning for risk of severe cutaneous adverse reactions, such as Stevens-Johnson syndrome
Tegretol (carbamazepine): warning for risk of hyponatremia and a contraindication for patients with rare hereditary problems of fructose intolerance